

Curriculum vitae – Torstein Baade Rø

PERSONAL INFORMATION

Name: Rø, Torstein Baade (male)
Date of birth: 16th Jan 1971.
Nationality: Norwegian
ORCID: 0000-0002-5258-500X
Home page: www.ntnu.edu/employees/torstein.ro

EDUCATION

2006 Dr. med., Medical Faculty, Norwegian University of Science and Technology, Trondheim, Norway
1996 Cand. med., Medical Faculty, Norwegian University of Science and Technology, Trondheim, Norway

Certified as a specialist in Pediatrics by the Norwegian Health Authorities (2008). University courses with exams in management (2016, 22.5 sp), pedagogics (2017, 15 sp), psychology (1996, 60 sp). Certified for animal experiments FELASA-C (2002) and Good Clinical Practice (2018).

CURRENT POSITION

2017- Head of Department/associate professor, Dept. of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway and adjunct 20% position as consultant at Dept. of Pediatrics, St. Olav's Hospital, Trondheim, Norway

PREVIOUS POSITIONS HELD

2011-2017 Head of Unit for pediatric medicine at Dept. of Pediatrics, St. Olav's Hospital, Trondheim, Norway (50%).
2014-2017 Associate professor at Dept. of Laboratory Medicine, Women's and Children's Health, NTNU, Trondheim, Norway (50%) and researcher at Dept. of Cancer Research and Molecular Medicine (20-50%).
2010-2014 Postdoc at Dept. of Cancer Research and Molecular Medicine, NTNU (50%).
2006-2010 Consultant at Dept. of Pediatrics, St. Olav's Hospital, Trondheim, Norway (100%) and Associate professor at Dept. of Laboratory Medicine, Women's and Children's Health, NTNU (20%)
2005-2006 Resident at Dept. of Pediatrics, St. Olav's Hospital, Trondheim, Norway

2001-2004	PhD student at Dept. of Cancer Research and Molecular Medicine, NTNU
1999-2000	Resident at Dept. of Pediatrics, St. Olav's Hospital, Trondheim, Norway
1997-1999	Internship ("Turnustjeneste") and army duties

FELLOWSHIPS, AWARDS AND PRIZES

2014	Scholarship (NOK 50.000) from Odd Fellow Foundation
------	---

PROJECT MANAGEMENT EXPERIENCE

2017-2022	Rehabilitation of adolescents with CFS/ME. Role: Project manager. Funding from Health and Care Ministry, St. Olav's Hospital, NTNU, Oslo University Hospital 5 MNOK
2017-2022	Cognitive Rehabilitation in Pediatric Acquired Brain Injury. A randomized controlled study. Role: Project manager. Funded by the Norwegian Research Council and St. Olav's Hospital 15 MNOK
2014-2019	Impaired awareness of hypoglycaemia, a multi-centre observational study. Role: Project manager. Funded by Central Norway Regional Health Authorities and the Norwegian Diabetes Association 4 MNOK
2014-2018	The phosphatase PRL-3 in B-cell malignancies. Role: Project manager. Funded by Central Norway Regional Health Authorities and the Cancer Society 7 MNOK

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

2013-	9 PhD-students, 3 as main supervisor (1 completed) and 6 as co-supervisor (3 completed). All at NTNU except one (Oslo University Hospital).
2011-2013	2 Master students (all completed), Master of clinical health sciences. All at NTNU.
2014-2017	6 Cand.med. (all completed), Medical Student Thesis (30 sp). All at NTNU.

TEACHING ACTIVITIES

2006-	Regular teaching of medical students and nurses/specialized nurses mainly within the field of pediatrics (lectures, seminars, problem-based learning etc.).
2011-	Regular lectures at courses hosted by the Norwegian Medical Association for general practitioners and specialist candidates in pediatrics

COMMISSIONS OF TRUST

2018-	Advisor for the Norwegian Medicinal Agency
2017-	Chair of steering group, RCN Center of Excellence, Centre of Molecular Inflammation Research (CEMIR)
2017-	Advisor for European network for Health Technology Assessment (EUnetHTA)
2017-	Board member, bioinformatics network ELIXIR Norway
2017-	Advisor for diabetes, Norwegian Institute of Public Health
2016-17	Vice head of department, Dept. of Laboratory Medicine, Women's and Children's Health, NTNU
2016-17	Unit leader for pediatrics, Dept. of Laboratory Medicine, Women's and Children's Health, NTNU
2016-	Board member, the Norwegian Study-group for childhood and adolescent diabetes.
2016-19	Scientific evaluator for Regional Health Authority North-Norway
2015-18	Member of steering group, RCN-project BIOTEK 2021, SINTEF
2013-15	Scientific evaluator for Regional Health Authority Mid-Norway
2013-17	Scientific evaluator for Fylkesmanns H.B. Guldahls legat
2012-15	Member of Directorate of Health advisory board on CFS/ME
2012-13	Member of ALL-CNS subgroup in NOPHO (Nordic Society of Pediatric Hematology and Oncology)
2011-19	Member of Lilly Advisory Board for childhood diabetes
2010-17	Chair of reference group, national treatment service for intersex disorders.
2010-	Board member, National group for pediatric endocrinology
2010-11	Member of reference group «Diabetes i Helse Midt-Norge 2012-16»
2002-	Reviewer for a number of journals including Blood, Oncogene and European Journal of Hematology

Track record

A total of 30 original publications in international peer-reviewed journals indexed in NSD, H-index 13, citations 598 excluding self-citations.

SELECTED PUBLICATIONS

1. Brenne AT*, Rø TB*, Waage A, Sundan A, Børset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002 May 15;99(10):3756-62.
*Shared authors. Level: 2. Citations: 125
2. Rø TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner Ø, Sundan A, Børset M. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2004 Apr 15;23(17):3024-32. Level: 2. Citations: 90
3. Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand J Clin Lab Invest. 2012 Nov;72(7):570-5. Level: 1. Citations: 41
4. Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M. HGF and IGF-1 synergize with SDF-1 α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol. 2013 Jul;41(7):646-55. Level: 1. Citations: 15

5. Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, **Rø TB**. Anti-c-Met Nanobody – A New Potential Drug in Multiple Myeloma Treatment. *Eur J Hematol*. 2013 Nov;91(5):399-410. Level: 1. Citations: 15
6. Hjort MA, Abdollahi P, Vansemb EN, Fenstad MH, Lund B, Slørdahl TS, Børset M, **Rø TB**. Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance. *Oncotarget*. 2017 Dec 13;9(3): 3549-3561. Level: 1. Citations: 4
7. Ingul CB, Dias KA, Tjonna AE, Follestad T, Hosseini MS, Timilsina AS, Hollekim-Strand SM, **Rø TB**, Davies PS, Cain PA, Leong GM, Coombes JS. Effect of High Intensity Interval Training on Cardiac Function in Children with Obesity: A Randomised Controlled Trial. *Prog Cardiovasc Dis*. 2018 Jul; 61(2):214-221. Level: 2. Citations: 7
8. Hjort MA, Hov H, Abdollahi P, Vandsemb EN, Fagerli UM, Lund B, Slørdahl TS, Børset M, **Rø TB**. Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration. *Exp Hematol Oncol*. 2018 Apr 10;7:8. Doi: 10.1186/s40164-018-0100-2. Level: 1. Citations: 3
9. Hyper RE, Brandt AE, Risnes K, **Rø TB**, Skovlund E, Andersson S, Finnanger TG, Stubberud J. Paediatric goal management training in patients with acquired brain injury: study protocol for a randomized controlled trial. *BMJ Open* 2019 Aug; 9(8):e029273. Level: 1. Citations: 0
10. Hatle H, Bjørgaas MR, Skrivarhaug T, Åsvold BO, Graveling AJ, Frier BM, **Rø TB**. Assessing awareness of hypoglycemia in children and adolescents with type 1 diabetes: Evaluation of established questionnaires. *Pediatr Diabetes* 2019 Dec; doi: 10.1111/pedi. 12951. Level: 1. Citations: 0